Cyclobenzaprine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Cyclobenzaprine

Examples of brand names: Flexeril [USA]

ATC code: M03BX08

Main use (for orientation): Muscle spasms

Documented research summary

Within the documented search scope, no sufficiently attributable cannabinoid pair is established for Cyclobenzaprine. The structured assessment distinguishes documented drug context from the absence of specific interaction evidence. Missing data do not establish safety.

Uncertainties and limitations

No established pair-specific serotonin-syndrome or concentration effect; full-text question remains open. Do not independently change prescribed medicines on the basis of this research dataset.

Structured assessment

Category: Drug context

Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.

Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.

Mechanism / drug context: CYP3A4 and CYP1A2, with less CYP2D6; sedating and anticholinergic properties.

Type of supporting material: Product information and documented individual literature screening; no clinical pair trial approved for use as evidence.

Clinical interpretation: Possible additional impairment must not be classified as a clinically demonstrated cannabinoid interaction.

Context: A report cited in the review does not identify a sufficiently specified cyclobenzaprine–cannabinoid pair in the accessible abstract.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [V2_LABEL_D0181]: Original product information: drug context, not evidence for a cannabinoid–drug pair

Statement supported: CYP3A4 and CYP1A2, with less CYP2D6; sedating and anticholinergic properties.

Source: CYCLOBENZAPRINE HYDROCHLORIDE (CYCLOBENZAPRINE HYDROCHLORIDE) TABLET, FILM COATED [REMEDYREPACK INC.] [V2_LABEL_D0181]

Source role [CA_P_40738618]: Documented research / scope-distinction context; no cannabinoid–drug pair evidence approved for use

Statement supported: A report cited in the review does not identify a sufficiently specified cyclobenzaprine–cannabinoid pair in the accessible abstract.

Source: Urinary metabolic ratio of pain management and substance abuse treatment drugs: Drug-drug interactions. [CA_P_40738618]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. No established pair-specific serotonin-syndrome or concentration effect; full-text question remains open.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[V2_LABEL_D0181] CYCLOBENZAPRINE HYDROCHLORIDE (CYCLOBENZAPRINE HYDROCHLORIDE) TABLET, FILM COATED [REMEDYREPACK INC.]

Original source / bibliographic reference

Authors: REMEDYREPACK INC.

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_40738618] Urinary metabolic ratio of pain management and substance abuse treatment drugs: Drug-drug interactions.

Original source / bibliographic reference

Authors: Cua A, Wickett E, Pesce AJ.

Year: 2025

Source type: Journal Article

DOI: 10.5055/jom.0907

PMID: 40738618

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility